Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study.
Narita I, Hayashi T, Maruyama S, Masaki T, Nangaku M, Nishino T, Sato H, Sofue T, Wada T, Imai E, Iwasaki M, Mizuno K, Hase H, Kamouchi M, Yamamoto H, Kagimura T, Tanabe K, Kato H, Wada T, Usui T, Akizawa T, Hirakata H, Tsubakihara Y. Narita I, et al. Among authors: mizuno k. PLoS One. 2022 Nov 29;17(11):e0277921. doi: 10.1371/journal.pone.0277921. eCollection 2022. PLoS One. 2022. PMID: 36445882 Free PMC article.
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Kato H, et al. Among authors: mizuno k. Clin Exp Nephrol. 2018 Feb;22(1):78-84. doi: 10.1007/s10157-017-1427-4. Epub 2017 Jun 28. Clin Exp Nephrol. 2018. PMID: 28660446 Free PMC article.
Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan.
Hayashi T, Kato H, Tanabe K, Nangaku M, Hirakata H, Wada T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Hayashi T, et al. Among authors: mizuno k. Clin Exp Nephrol. 2021 Feb;25(2):110-119. doi: 10.1007/s10157-020-01969-7. Epub 2020 Sep 19. Clin Exp Nephrol. 2021. PMID: 32949295 Free PMC article.
Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Kato H, et al. Among authors: mizuno k. Clin Exp Nephrol. 2018 Feb;22(1):85-86. doi: 10.1007/s10157-017-1461-2. Clin Exp Nephrol. 2018. PMID: 28875480 Free PMC article. No abstract available.
Separation of the subtypes of type V collagen molecules, [alpha 1(V)]2 alpha 2(V) and alpha 1(V) alpha 2(V) alpha 3(V), by chain composition-dependent affinity for heparin: single alpha 1(V) chain shows intermediate heparin affinity between those of the type V collagen subtypes composed of [alpha 1(V)]2 alpha 2(V) and of alpha 1(V) alpha 2(V) alpha 3(V).
Mizuno K, Hayashi T. Mizuno K, et al. J Biochem. 1996 Nov;120(5):934-9. doi: 10.1093/oxfordjournals.jbchem.a021509. J Biochem. 1996. PMID: 8982859 Free article.
Lifelog Data Suggest Decreased Physical Activity Across Cancer Diagnosis and Treatment: Analysis Using Smartphone Step Count Data Linked to a Japanese Claims Database.
Inayama Y, Yamaguchi K, Mizuno K, Tanaka-Mizuno S, Koike A, Higashiyama N, Taki M, Yamanoi K, Murakami R, Hamanishi J, Yoshida S, Mandai M, Kawakami K. Inayama Y, et al. Among authors: mizuno k. JMIR Cancer. 2024 Dec 16. doi: 10.2196/58093. Online ahead of print. JMIR Cancer. 2024. PMID: 39726139
3,257 results